SCLERODERMA, SYSTEMIC

This study tested whether imatinib, a drug used for certain cancers, can reduce skin hardening in people with severe scleroderma. 28 adults received either imatinib or a placebo for 6 months. The main goal was to see if the drug improved skin thickness and quality of life.

This study tested a medicine called Avenciguat (BI 685509) in 214 adults with scleroderma, a disease that can cause skin hardening and lung or blood vessel damage. Participants took either the study drug or a placebo three times daily for at least 11 months. Researchers measured …

This study tested whether tofacitinib (a JAK inhibitor drug) works better than methotrexate (a standard treatment) at reducing skin thickening in people with a severe form of scleroderma called diffuse cutaneous systemic sclerosis. Thirty-four adults with early-stage disease took…

This study examined whether women with autoimmune diseases or inflammatory rheumatism receive proper gynecological follow-up, including cervical cancer screening and contraception advice. Researchers surveyed 318 women with conditions like lupus, rheumatoid arthritis, and Sjögren…

This completed study looked at how certain immune cells (T cells and NK cells) might damage blood vessels in people with systemic sclerosis, a rare autoimmune disease. Researchers analyzed blood samples from 30 participants to measure a protein called Fractalkine and study cell i…

This study looked at 30 adults with scleroderma, an autoimmune disease that often causes hand stiffness and disability. Researchers measured how much movement was limited in each hand to compare the dominant and non-dominant sides. The goal was to better understand hand function …

This study looked at how B cells, a type of immune cell, may contribute to scarring in people with systemic sclerosis (scleroderma). Researchers compared skin and blood samples from 71 participants, including patients and healthy volunteers. The goal was to understand the disease…